Chromosome 9 instability and alterations of p16 gene in squamous cell carcinoma of the lung and in adjacent normal bronchi: FISH and immunohistochemical study

Histopathology

Volumn 52, Issue 4, 2008, Pages 475-482

  Dessy, E ^a,b   Rossi, E ^b   Berenzi, A ^b   Tironi, A ^b   Benetti, A ^b   Grigolato, P ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

FISH; Immunohistochemistry; Lung; p16 inactivation; Squamous cell carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 6; PROTEIN P16;

ADULT; AGED; ARTICLE; BRONCHUS MUCOSA; CELL CYCLE REGULATION; CHROMOSOMAL INSTABILITY; CHROMOSOME 9; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE INACTIVATION; GENE MUTATION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG CARCINOMA; MALE; P16 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; BRONCHI; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CHROMOSOMAL INSTABILITY; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 40149097600     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.02969.x     Document Type: Article

References (31)

1. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur. J. Cancer 2002 38 99 166.
2. Tyczynski JE, Bray F, Parkin DM. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol. 2003 4 45 55.
3. Janssen-Heijnen MLG, Coebergh J-WW. The changing epidemiology of lung cancer in Europe. Lung Cancer 2003 41 245 258.
4. Didkowska J, Manczuk M, McNeill A et al. Lung cancer mortality at ages 35-54 in the European Union: ecological study of evolving tobacco epidemics. BMJ 2005 331 189 191.
5. Wistuba II, Gazdar AF. Lung cancer preneoplasia. Ann. Rev. Pathol. Mech. Dis. 2006 1 331 348.
6. Wistuba II, Behren SC, Milchgrub S et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999 18 643 650.
7. INK4a in normal epithelium of patients with primary lung cancer. Genes Chromosome Cancer 2001 32 119 125.
8. Park IW, Wistuba II, Maitra A et al. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J. Natl. Cancer Inst. 1999 91 1863 1868.
9. Mao L. Molecular abnormalities in lung carcinogenesis and their potential clinical implications. Lung Cancer 2001 34 S27 S34.
10. INK4a and RASSF1 a promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer, Clin. Cancer Res. 2004 10 6119 6125.
11. Tanaka R, Wang D, Morishita Y et al. Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer 2005 103 608 615.
12. INK4A inactivation in non small-cell lung cancers. Oncogene 1998 16 497 504.
13. Groeger AM, Caputi M, Esposito V et al. Independent prognostic role of p16 expression in lung cancer. J. Thorac. Cardiovasc. Surg. 1999 118 529 535.
14. Belinsky SA, Nikula KJ, Palmisano WA et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. U.S.A. 1998 95 11891 11896.
15. Serrano M, Gomez-Lahos E, Depinho RA et al. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995 267 249 252.
16. Jin M, Inoue S, Umemura T et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001 34 207 218.
17. Liggett WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol. 1998 16 1197 1206.
18. Gonzáles-Quevedo R, Iniesta P, Morán P et al. Cooperative role of telomerase activity and p16 expression in the prognosis of non-small-cell lung cancer. J. Clin. Oncol. 2002 20 254 262.
19. Jeanmart M, Lantuejoul S, Fievet F et al. Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin. Cancer Res. 2003 9 2195 2203.
20. Mountain CF. Revisions in International System for staging lung cancer. Chest 1997 111 1710 1717.
21. Gal AA, Marchevsky AM, Travis WD. Updated protocol for the examination of specimens from patients with carcinoma of the lung. Arch. Pathol. Lab. Med. 2003 127 1304 1313.
22. Qian J, Bostwick DG, Takahashi S et al. Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Am. J. Pathol. 1996 49 1193 1199.
23. INK4a and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 2001 61 3419 3424.
24. Awaya H, Takeshima Y, Amatya VJ et al. Inactivation of the p16 gene by hypermethylation and loss of heterozygosity in adenocarcinoma of the lung. Pathol. Int. 2004 54 486 489.
25. Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000 60 5954 5958.
26. INK4a promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J. Clin. Oncol. 2000 18 3221 3229.
27. Zöchbauer-Müller S, Minna JD, Gazdar AF. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 2002 7 451 457.
28. Okami K, Cairns P, Westra WH et al. Detailed deletion mapping at chromosome 9p21 in non-small cell lung cancer by microsatellite analysis and fluorescence in situ hybridization. Int. J. Cancer (Pred. Oncol.) 1997 74 588 592.
29. Sanchez-Cespedes M, Decker PA, Doffek KM et al. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res. 2001 61 2092 2096.
30. INK4a expression in resected non-small cell lung tumors. Cancer Res. 1996 56 3415 3420.
31. INK4a-cyclin D1) in preinvasive bronchial lesions. Clin. Cancer Res. 1999 5 243 250.